UPCC 19223 Open-Label Dose-Finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients with Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroeso
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol Section 2.1.1 (Main objectives). Please refer to Protocol Section 2.1.2 (Primary endpoint(s). Please refer to Protocol Section 2.1.4 (Secondary endpoints).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854518
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
